TNXPTonix Pharmaceuticals Holdi...

Nasdaq tonixpharma.com


$ 0.18 $ 0.00 (1.69 %)    

Thursday, 02-May-2024 14:12:37 EDT
QQQ $ 426.72 $ 1.50 (0.35 %)
DIA $ 382.25 $ 0.64 (0.17 %)
SPY $ 504.70 $ 0.30 (0.06 %)
TLT $ 88.96 $ 0.72 (0.82 %)
GLD $ 213.50 $ 1.04 (0.49 %)
$ 0.177
$ 0.18
$ 0.00 x 0
$ 0.00 x 0
$ 0.18 - $ 0.18
$ 0.12 - $ 3.31
1,197,255
na
3.02M
$ -0.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-13-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-24-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-13-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 04-13-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-05-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 03-03-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 02-27-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-08-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://twitter.com/DrTedros/status/1778423967105139108  

 tonix-pharmaceuticals-q4-eps-086-beats-155-estimate-sales-380m-miss-575m-estimate

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of...

 tonix-pharmaceuticals-stock-tnxp-hits-a-new-all-time-low-whats-going-on

Tonix Pharmaceuticals shares are trading lower by 7.2% Monday. The company last week announced the pricing of a $4.4 million re...

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 why-tonix-pharmaceuticals-stock-tnxp-is-getting-obliterated

Tonix Pharmaceuticals shares are trading lower by 22.3% Thursday afternoon. The company announced the pricing of a $4.4 million...

 tonix-pharmaceuticals-receives-rare-pediatric-disease-designation-from-the-fda-for-tnx-2900-for-the-treatment-of-prader-willi-syndrome

TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces ...

 tonix-pharmaceuticals-announces-poster-presentation-describing-discovery-of-novel-next-generation-oxytocin-analogues-at-the-american-chemistry-society-spring-2024-meeting

Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, bi...

 tonix-pharmaceuticals-announces-transition-to-fully-integrated-biopharmaceutical-company-expected-on-april-1-2024

Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiary Commercial...

 tonix-pharmaceuticals-announces-publication-in-psychiatry-research-showing-activity-of-bedtime-tnx-102-sl-on-ptsd-symptoms-and-sleep-quality-in-military-related-ptsd-at-four-weeks-of-therapy

Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR) and freque...

 tonix-pharmaceuticals-selects-eversana-to-support-launch-strategy-and-commercialization-planning-of-tonmya-for-the-management-of-fibromyalgia

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by st...

 tonix-pharmaceuticals-announces-translation-of-preclinical-pharmacokinetic-parameters-of-tnx-1500-supports-monthly-iv-dosing-in-humans

TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation m...

 dawson-james-initiates-coverage-on-tonix-pharmaceuticals-with-buy-rating-announces-price-target-of-3

Dawson James analyst Jason Kolbert initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces...

 tonix-pharmaceuticals-completes-clinical-stage-of-phase-1-trial-for-tnx-1500-in-healthy-volunteers

Topline results expected in the third quarter of 2024; planning a Phase 2 Trial for prevention of kidney transplant rejection A...

 tonix-pharmaceuticals-announces-results-from-clinical-pharmacokinetic-bridging-study-of-tonmya-to-support-development-and-partnering-in-japan-and-china

Tonix plans to File a Clinical Trial Notification (CTN) in Japan and Investigational New Drug (IND) application in China to sup...

 tonix-pharmaceuticals-announces-new-drug-study-shows-improving-sleep-quality-can-relieve-fibromyalgia-pain

Bedtime drug being developed by Tonix relieved pain by targeting fibromyalgia's characteristic "non-restorative sleep&#...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION